Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
about
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.Targeting postprandial glycaemia in children with diabetes: Opportunities and challenges.A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
P2860
Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Upper and/or lower gastrointes ...... s: Incidence and consequences.
@ast
Upper and/or lower gastrointes ...... s: Incidence and consequences.
@en
type
label
Upper and/or lower gastrointes ...... s: Incidence and consequences.
@ast
Upper and/or lower gastrointes ...... s: Incidence and consequences.
@en
prefLabel
Upper and/or lower gastrointes ...... s: Incidence and consequences.
@ast
Upper and/or lower gastrointes ...... s: Incidence and consequences.
@en
P2093
P2860
P356
P1476
Upper and/or lower gastrointes ...... s: Incidence and consequences.
@en
P2093
Elise Hardy
Michael Horowitz
Vanita R Aroda
P2860
P304
P356
10.1111/DOM.12872
P577
2017-01-06T00:00:00Z